Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Bruce I Sachs. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Bruce I Sachs har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:VRTX / Vertex Pharmaceuticals Incorporated | Director | 45 000 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Bruce I Sachs. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Bruce I Sachs som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 3 366 | 45 000 | 8,08 | 389,84 | 1 312 201 | 17 542 800 | |
2025-08-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 1 634 | 41 634 | 4,08 | 389,36 | 636 214 | 16 210 614 | |
2024-08-02 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 295 | 40 000 | −11,69 | 508,00 | −2 689 860 | 20 320 000 |
2024-08-02 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 5 295 | 45 295 | 13,24 | 125,71 | 665 634 | 5 694 034 | |
2024-05-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −7 073 | 40 000 | −15,03 | 448,00 | −3 168 704 | 17 920 000 |
2024-05-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 7 073 | 47 073 | 17,68 | 93,51 | 661 396 | 4 401 796 | |
2023-11-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −11 250 | 40 000 | −21,95 | 385,00 | −4 331 250 | 15 400 000 |
2023-11-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 11 250 | 51 250 | 28,12 | 127,54 | 1 434 825 | 6 536 425 | |
2023-07-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −3 842 | 40 000 | −8,76 | 357,29 | −1 372 708 | 14 291 600 |
2023-07-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 711 | 43 842 | −11,53 | 356,75 | −2 037 399 | 15 640 634 |
2023-07-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 697 | 49 553 | −3,31 | 355,54 | −603 351 | 17 618 074 |
2023-07-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 11 250 | 51 250 | 28,12 | 127,54 | 1 434 825 | 6 536 425 | |
2023-04-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
G - Gift | −1 210 | 40 000 | −2,94 | ||||
2023-04-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −8 026 | 41 210 | −16,30 | 327,48 | −2 628 354 | 13 495 451 |
2023-04-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −10 357 | 49 236 | −17,38 | 326,46 | −3 381 146 | 16 073 585 |
2023-04-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 917 | 59 593 | −4,67 | 325,65 | −949 921 | 19 406 460 |
2023-04-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 21 300 | 62 510 | 51,69 | 72,14 | 1 536 582 | 4 509 471 | |
2023-02-02 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 200 | 41 210 | −2,83 | 325,01 | −390 012 | 13 393 662 |
2023-02-02 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 1 200 | 42 410 | 2,91 | 72,14 | 86 568 | 3 059 457 | |
2022-05-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 4 462 | 4 462 | |||||
2022-04-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 151 | 13 824 | 1,11 | 289,41 | 43 750 | 4 000 661 | |
2022-01-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 190 | 13 672 | 1,41 | 230,58 | 43 750 | 3 152 568 | |
2021-10-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 240 | 13 483 | 1,81 | 182,07 | 43 750 | 2 454 777 | |
2021-08-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 15 000 | 41 210 | 57,23 | 197,91 | 2 968 650 | 8 155 871 | |
2021-07-16 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 221 | 13 242 | 1,70 | 198,00 | 43 750 | 2 621 977 | |
2021-05-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 6 067 | 6 067 | |||||
2021-04-16 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 199 | 13 021 | 1,55 | 220,17 | 43 750 | 2 866 910 | |
2021-01-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 194 | 12 823 | 1,53 | 225,99 | 43 750 | 2 897 787 | |
2020-11-12 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 3 905 | 26 210 | 17,51 | 218,79 | 854 375 | 5 734 486 | |
2020-11-12 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 4 270 | 22 305 | 23,68 | 217,49 | 928 682 | 4 851 114 | |
2020-11-12 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 6 825 | 18 035 | 60,88 | 216,47 | 1 477 408 | 3 904 036 | |
2020-10-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 196 | 12 629 | 1,58 | 222,81 | 43 750 | 2 813 877 | |
2020-07-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 155 | 12 433 | 1,26 | 292,77 | 45 453 | 3 639 917 | |
2020-06-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 4 527 | 4 527 | |||||
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −22 500 | 0 | −100,00 | ||||
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −22 500 | 0 | −100,00 | ||||
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 960 | 11 210 | −20,89 | 272,46 | −806 482 | 3 054 277 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −6 232 | 14 170 | −30,55 | 271,63 | −1 692 798 | 3 848 997 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 889 | 20 402 | −22,40 | 270,49 | −1 592 916 | 5 518 537 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −15 751 | 26 291 | −37,46 | 269,53 | −4 245 367 | 7 086 213 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −11 568 | 42 042 | −21,58 | 268,65 | −3 107 743 | 11 294 583 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 600 | 53 610 | −4,63 | 267,50 | −695 500 | 14 340 675 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 22 500 | 56 210 | 66,75 | 81,54 | 1 834 650 | 4 583 363 | |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 22 500 | 33 710 | 200,71 | 59,55 | 1 339 875 | 2 007 430 | |
2020-04-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 179 | 12 277 | 1,48 | 258,56 | 46 250 | 3 174 453 | |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −20 000 | 0 | −100,00 | ||||
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −100 | 11 210 | −0,88 | 235,40 | −23 540 | 2 638 834 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −900 | 11 310 | −7,37 | 234,15 | −210 735 | 2 648 236 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 800 | 12 210 | −12,85 | 233,13 | −419 634 | 2 846 517 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 200 | 14 010 | −7,89 | 232,04 | −278 448 | 3 250 880 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 200 | 15 210 | −7,31 | 230,87 | −277 044 | 3 511 533 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −500 | 16 410 | −2,96 | 229,90 | −114 950 | 3 772 659 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −600 | 16 910 | −3,43 | 228,33 | −136 998 | 3 861 060 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −300 | 17 510 | −1,68 | 227,66 | −68 298 | 3 986 327 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 644 | 17 810 | −24,06 | 227,01 | −1 281 244 | 4 043 048 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −4 198 | 23 454 | −15,18 | 226,32 | −950 091 | 5 308 109 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 858 | 27 652 | −6,30 | 224,98 | −418 013 | 6 221 147 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 700 | 29 510 | −5,45 | 224,02 | −380 834 | 6 610 830 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 20 000 | 31 210 | 178,41 | 53,85 | 1 077 000 | 1 680 658 | |
2020-01-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 200 | 12 099 | 1,68 | 231,55 | 46 250 | 2 801 421 | |
2019-10-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 264 | 11 899 | 2,26 | 175,50 | 46 250 | 2 088 242 | |
2019-07-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 257 | 11 635 | 2,26 | 176,39 | 45 371 | 2 052 348 | |
2019-06-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 1 801 | 11 378 | 18,81 | ||||
2019-06-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 6 659 | 6 659 | |||||
2019-06-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
D - Sale to Issuer | −1 801 | 11 210 | −13,84 | ||||
2019-04-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 247 | 9 577 | 2,65 | 182,28 | 45 000 | 1 745 707 | |
2019-01-16 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 243 | 9 330 | 2,68 | 184,90 | 45 000 | 1 725 152 | |
2019-01-02 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
G - Gift | −10 000 | 13 011 | −43,46 | ||||
2018-12-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −10 000 | 0 | −100,00 | ||||
2018-12-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 10 000 | 23 011 | 76,86 | 34,24 | 342 400 | 787 897 | |
2018-10-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 251 | 9 087 | 2,84 | 179,29 | 45 000 | 1 629 175 | |
2018-07-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 249 | 8 836 | 2,90 | 180,97 | 45 000 | 1 599 019 | |
2018-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 2 188 | 8 587 | 34,19 | ||||
2018-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 3 229 | 3 229 | |||||
2018-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
D - Sale to Issuer | −2 188 | 13 011 | −14,40 | ||||
2018-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 1 801 | 15 199 | 13,44 | ||||
2018-04-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 280 | 6 399 | 4,57 | 160,89 | 45 000 | 1 029 561 | |
2018-01-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 262 | 6 119 | 4,47 | 157,50 | 41 250 | 963 816 | |
2018-01-17 |
|
5 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
G - Gift | −10 000 | 13 398 | −42,74 | ||||
2017-10-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 265 | 5 858 | 4,75 | 155,44 | 41 250 | 910 500 | |
2017-07-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 317 | 5 592 | 6,01 | 130,15 | 41 250 | 727 823 | |
2017-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 2 941 | 5 275 | 125,99 | ||||
2017-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 5 295 | 5 295 | |||||
2017-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
D - Sale to Issuer | −2 941 | 23 398 | −11,17 | ||||
2017-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 2 188 | 26 339 | 9,06 | ||||
2017-04-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 360 | 2 334 | 18,24 | 114,58 | 41 250 | 267 458 | |
2017-01-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 508 | 1 974 | 34,67 | 81,16 | 41 250 | 160 229 | |
2016-10-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 516 | 1 466 | 54,25 | 80,01 | 41 250 | 117 293 | |
2016-07-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 461 | 950 | 94,25 | 89,45 | 41 250 | 85 015 | |
2016-06-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 7 073 | 7 073 | |||||
2016-06-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 2 941 | 24 151 | 13,87 | 0,01 | 29 | 242 | |
2016-04-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 489 | 489 | 87,60 | 42 860 | 42 860 | ||
2015-08-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −10 000 | 10 000 | −50,00 | ||||
2015-08-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −10 000 | 21 210 | −32,04 | 140,13 | −1 401 300 | 2 972 157 |
2015-08-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 10 000 | 31 210 | 47,15 | 34,24 | 342 400 | 1 068 630 | |
2015-06-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option |
A - Award | 22 500 | 22 500 | |||||
2015-03-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −10 000 | 0 | −100,00 | ||||
2015-03-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 375 | 21 210 | −6,09 | 136,14 | −187 192 | 2 887 529 |
2015-03-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −8 625 | 22 585 | −27,64 | 135,42 | −1 167 998 | 3 058 461 |
2015-03-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 10 000 | 31 210 | 47,15 | 29,89 | 298 900 | 932 867 | |
2015-03-20 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −10 000 | 10 000 | −50,00 | ||||
2015-03-20 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −10 000 | 21 210 | −32,04 | 130,13 | −1 301 300 | 2 760 057 |
2015-03-20 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 10 000 | 31 210 | 47,15 | 29,89 | 298 900 | 932 867 | |
2015-01-22 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −139 | 0 | −100,00 | ||||
2015-01-22 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −139 | 21 210 | −0,65 | 125,00 | −17 375 | 2 651 250 |
2015-01-22 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 139 | 21 349 | 0,66 | 28,40 | 3 948 | 606 312 | |
2015-01-13 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −9 861 | 139 | −98,61 | ||||
2015-01-13 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −9 861 | 21 210 | −31,74 | 125,04 | −1 233 019 | 2 652 098 |
2015-01-13 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 9 861 | 31 071 | 46,49 | 28,40 | 280 052 | 882 416 | |
2014-12-01 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −10 000 | 10 000 | −50,00 | ||||
2014-12-01 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −10 000 | 21 210 | −32,04 | 120,03 | −1 200 300 | 2 545 836 |
2014-12-01 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 10 000 | 31 210 | 47,15 | 28,40 | 284 000 | 886 364 | |
2014-11-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −9 900 | 0 | −100,00 | ||||
2014-11-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −9 900 | 21 210 | −31,82 | 115,21 | −1 140 579 | 2 443 604 |
2014-11-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 9 900 | 31 110 | 46,68 | 29,84 | 295 416 | 928 322 | |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −100 | 9 900 | −1,00 | ||||
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −100 | 21 210 | −0,47 | 111,86 | −11 186 | 2 372 551 |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 100 | 21 310 | 0,47 | 29,84 | 2 984 | 635 890 | |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −10 000 | 10 000 | −50,00 | ||||
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −100 | 21 210 | −0,47 | 115,45 | −11 545 | 2 448 694 |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −4 400 | 21 310 | −17,11 | 114,23 | −502 612 | 2 434 241 |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −3 200 | 25 710 | −11,07 | 113,47 | −363 104 | 2 917 314 |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 300 | 28 910 | −7,37 | 112,47 | −258 681 | 3 251 508 |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 10 000 | 31 210 | 47,15 | 29,84 | 298 400 | 931 306 | |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −20 000 | 0 | −100,00 | ||||
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 684 | 21 210 | −11,23 | 112,80 | −302 755 | 2 392 488 |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −17 316 | 23 894 | −42,02 | 112,03 | −1 939 911 | 2 676 845 |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 20 000 | 41 210 | 94,30 | 34,32 | 686 400 | 1 414 327 | |
2014-06-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option |
A - Award | 22 500 | 22 500 | |||||
2014-03-25 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −500 | 21 210 | −2,30 | 76,57 | −38 285 | 1 624 050 |
2014-03-25 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −3 000 | 21 710 | −12,14 | 75,25 | −225 750 | 1 633 678 |
2014-03-25 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 750 | 24 710 | −10,01 | 74,47 | −204 792 | 1 840 154 |
2014-03-25 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 450 | 27 460 | −8,19 | 73,53 | −180 148 | 2 019 134 |
2014-02-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −3 200 | 29 910 | −9,66 | 84,13 | −269 216 | 2 516 328 |
2014-02-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −3 800 | 33 110 | −10,30 | 83,65 | −317 870 | 2 769 652 |
2014-02-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 300 | 36 910 | −3,40 | 82,51 | −107 263 | 3 045 444 |
2014-01-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −400 | 38 210 | −1,04 | 86,91 | −34 764 | 3 320 831 |
2014-01-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 500 | 38 610 | −3,74 | 85,87 | −128 805 | 3 315 441 |
2014-01-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −600 | 40 110 | −1,47 | 84,90 | −50 940 | 3 405 339 |
2014-01-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 800 | 40 710 | −12,47 | 83,89 | −486 562 | 3 415 162 |
2013-12-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 200 | 46 510 | −2,52 | 73,45 | −88 140 | 3 416 160 |
2013-12-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −7 100 | 47 710 | −12,95 | 72,95 | −517 945 | 3 480 444 |
2013-11-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −200 | 54 810 | −0,36 | 67,15 | −13 430 | 3 680 492 |
2013-11-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 700 | 55 010 | −3,00 | 66,25 | −112 625 | 3 644 412 |
2013-11-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −4 900 | 56 710 | −7,95 | 65,35 | −320 215 | 3 705 998 |
2013-11-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −800 | 61 610 | −1,28 | 64,21 | −51 368 | 3 955 978 |
2013-11-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −700 | 62 410 | −1,11 | 63,10 | −44 170 | 3 938 071 |
2013-10-25 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 800 | 63 110 | −8,42 | 77,17 | −447 586 | 4 870 199 |
2013-10-25 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 500 | 68 910 | −3,50 | 76,80 | −192 000 | 5 292 288 |
2013-09-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 500 | 71 410 | −3,38 | 75,23 | −188 075 | 5 372 174 |
2013-09-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 800 | 73 910 | −7,28 | 74,86 | −434 188 | 5 532 903 |
2013-09-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −600 | 79 710 | −0,75 | 77,97 | −46 782 | 6 214 989 |
2013-09-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −6 010 | 80 310 | −6,96 | 77,29 | −464 513 | 6 207 160 |
2013-09-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 690 | 86 320 | −1,92 | 76,55 | −129 370 | 6 607 796 |
2013-07-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −600 | 88 010 | −0,68 | 87,03 | −52 218 | 7 659 510 |
2013-07-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 700 | 88 610 | −2,96 | 85,89 | −231 903 | 7 610 713 |
2013-07-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 000 | 91 310 | −5,19 | 85,10 | −425 500 | 7 770 481 |
2013-06-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 700 | 96 310 | −2,73 | 76,53 | −206 631 | 7 370 604 |
2013-06-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −4 500 | 99 010 | −4,35 | 75,85 | −341 325 | 7 509 908 |
2013-06-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 100 | 103 510 | −1,05 | 74,81 | −82 291 | 7 743 583 |
2013-06-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option |
A - Award | 22 500 | 22 500 | |||||
2013-05-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −4 262 | 104 610 | −3,91 | 80,63 | −343 645 | 8 434 704 |
2013-05-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 538 | 108 872 | −1,39 | 79,50 | −122 271 | 8 655 324 |
2013-05-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 500 | 110 410 | −2,21 | 78,48 | −196 200 | 8 664 977 |
2013-05-16 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | −60 000 | 112 910 | −34,70 | 81,15 | −4 869 000 | 9 162 646 | |
2013-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −7 000 | 172 910 | −3,89 | 77,41 | −541 870 | 13 384 963 |
2013-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 300 | 179 910 | −0,72 | 76,19 | −99 047 | 13 707 343 |
2012-06-01 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option |
A - Award | 22 500 | 22 500 |